A double-blind randomized study of sandimmun neoral versus sandimmun in new renal transplant recipients: Results after 12 months

Transplantation Proceedings

Volumn 27, Issue 2, 1995, Pages 1849-1856

  Niese, D ^a   Buchholz, B ^a   Land, W ^a   Vanrenterghem, Y ^a   May, G ^a   Abendroth, D ^a   Wiesel, M ^a   Kovarik, J ^a   Briggs, J D ^a   Sells, R A ^a   Vereerstraeten, P ^a   Largadier, F ^a   Frey, F ^a   Hardens, M ^a   Liesemer, A ^a   Krauss, M ^a   Schleibner, D ^a   Waer, M ^a   Mueller, P ^a  

^a Sandoz Pharma Ltd   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOSPORIN A; OKT 3; STEROID; THYMOCYTE ANTIBODY;

ADULT; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; FEMALE; GINGIVA HYPERPLASIA; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HYPERTRICHOSIS; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; ANTILYMPHOCYTE SERUM; AZATHIOPRINE; CREATININE; CYCLOSPORINE; DIASTOLE; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MUROMONAB-CD3; STEROIDS; SURVIVAL RATE; TIME FACTORS;

EID: 0028953549     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (0)